4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 78 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,014,828 | -42.6% | 158,274 | -18.5% | 0.00% | -100.0% |
| Q2 2023 | $3,510,369 | +3.2% | 194,265 | -1.8% | 0.00% | 0.0% |
| Q1 2023 | $3,400,216 | +29.4% | 197,802 | +67.1% | 0.00% | 0.0% |
| Q4 2022 | $2,628,420 | +211.4% | 118,344 | +12.6% | 0.00% | – |
| Q3 2022 | $844,000 | -9.4% | 105,070 | -21.3% | 0.00% | – |
| Q2 2022 | $932,000 | -18.3% | 133,563 | +77.0% | 0.00% | – |
| Q1 2022 | $1,141,000 | +55.2% | 75,458 | +125.3% | 0.00% | – |
| Q4 2021 | $735,000 | +181.6% | 33,495 | +245.8% | 0.00% | – |
| Q3 2021 | $261,000 | -51.8% | 9,686 | -22.4% | 0.00% | – |
| Q1 2021 | $542,000 | -82.6% | 12,486 | -83.3% | 0.00% | -100.0% |
| Q4 2020 | $3,108,000 | – | 74,978 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
| Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
| BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
| Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
| Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
| Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
| Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
| Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |